drugset / Trial / NCT05502731

Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis

NCT05502731

RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the effect of filgotinib on phenotype, B cell receptor (BCR) usage and functional parameters of circulating B cells expressing ACPA in patients with ACPA-positive RA that show incomplete response to standard, medium-dose methotrexate (MTX) monotherapy.

Timeline

Start
2022-10
Primary completion
2025-03
Completion
2025-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Filgotinib Small molecule 200 mg Oral

Indications